علاج مرض القرحة الهضمية مع عدوى الملوية البوابية النشطة — مرضى لم يتلقوا علاجاً سابقاً

DOI: 10.14309/ajg.0000000000002968

• We summarize treatment recommendations for patients with active H. pylori infection, as confirmed by a nonserological test, who have not been previously treated (i.e., "treatment-naive" patients) and those with persistent infection despite previous attempt(s) at eradication (i.e., "treatment-experienced" patients).
• Rifabutin triple therapy or PCAB dual therapy for 14 days are suitable alternatives as empiric therapy in patients without penicillin allergy.
• In treatment-naive patients with H. pylori infection, optimized BQT is recommended as a first-line treatment option (strong recommendation; moderate quality evidence).
• For treatment-naive patients with H. pylori infection, BQT (preferably optimized) for 14 days is the preferred option when the antibiotic susceptibility profile is unknown.
• All patients who are treated for H. pylori infection should undergo a test of cure with an appropriately conducted urea breath test, fecal antigen test, or biopsy-based test at least 4 wk after completion of therapy.